TABLE 1.
Demographic and clinical covariates of all transplants with COVID‐19 NAT results between March 15, 2020 and September 30, 2021, stratified by COVID‐19 NAT status
| Descriptive statistics | COVID‐19 NAT positive | COVID‐19 NAT negative | |
|---|---|---|---|
| Categorical variable | # (%) | # (%) | p‐value* |
| n | 269 (0.60%) | 44 550 (99.40%) | |
| Organ | |||
| Heart | 18 (6.70%) | 4953 (11.10%) | <.001 |
| Kidney | 187 (69.50%) | 23 782 (53.40%) | |
| Kidney‐pancreas | 5 (1.90%) | 1109 (2.50%) | |
| Liver | 57 (21.20%) | 11 206 (25.20%) | |
| Lung | 2 (0.70%) | 3313 (7.40%) | |
| COVID‐19 NAT location (onor) | |||
| Blood | 0 (0.00%) | 67 (0.20%) | .001 |
| Lower respiratory | 25 (9.30%) | 8152 (18.30%) | |
| Upper respiratory | 241 (89.60%) | 36 060 (80.90%) | |
| Other** | 3 (1.10%) | 271 (0.60%) | |
| DCD | |||
| Yes | 96 (35.70%) | 8351 (18.70%) | <.001 |
| Race (Donor) | |||
| White | 151 (56.10%) | 28 811 (64.70%) | .007 |
| Black | 51 (19.00%) | 7101 (15.90%) | |
| Hispanic | 60 (22.30%) | 6841 (15.40%) | |
| Asian | 2 (0.70%) | 1118 (2.50%) | |
| American Indian/Alaskan | 3 (1.10%) | 305 (0.70%) | |
| Hawaiian/Pacific Islander | 0 (0.00%) | 114 (0.30%) | |
| Multiracial | 2 (0.70%) | 260 (0.60%) | |
| Gender (Donor) | |||
| Male | 194 (72.10%) | 28 503 (64.00%) | .007 |
| Cause of death (Donor) | |||
| Anoxia | 91 (33.80%) | 20 568 (46.20%) | <.001 |
| Cerebrovascular/Stroke | 56 (20.80%) | 9109 (20.40%) | |
| Head trauma | 82 (30.50%) | 13 654 (30.60%) | |
| CNS tumor | 0 (0.00%) | 137 (0.30%) | |
| Other | 20 (7.40%) | 1078 (2.40%) | |
| COVID‐19 infection | 20 (7.40%) | 4 (0.00%) | |
| Downtime (Donor) | |||
| Yes | 62 (23.00%) | 20 096 (45.40%) | <.001 |
| CPR (Donor) | |||
| Yes | 90 (33.50%) | 24 356 (55.60%) | <.001 |
| Age group (Recipient) | |||
| Pediatric | 3 (1.10%) | 2038 (4.60%) | .010 |
| Race (Recipient) | |||
| White | 153 (56.90%) | 22 593 (50.70%) | .504 |
| Black | 59 (21.90%) | 10 616 (23.80%) | |
| Hispanic | 40 (14.90%) | 7655 (17.20%) | |
| Asian | 14 (5.20%) | 2678 (6.00%) | |
| American Indian/Alaskan | 1 (0.40%) | 373 (0.80%) | |
| Hawaiian/Pacific Islander | 1 (0.40%) | 185 (0.40%) | |
| Multiracial | 1 (0.40%) | 450 (1.00%) | |
| Gender (Recipient) | |||
| Male | 173 (64.30%) | 27 766 (62.30%) | .544 |
| Graft status | |||
| Failed | 8 (3.00%) | 2652 (6.00%) | .053 |
| Recipient status | |||
| Died | 5 (1.90%) | 2058 (4.60%) | .045 |
| Continuous variable | Median (IQR) | Median (IQR) | p‐value*** |
|---|---|---|---|
| COVID‐19 NAT to recovery (days) | 4 (2–23) | 3 (2–5) | <.001 |
| Age (years) (Donor) | 38 (28–50) | 37 (26–49) | .309 |
| Age (years) (Recipient) | 54 (43–63) | 55 (43–64) | .433 |
| Graft time since transplant (days) | 83 (31–164) | 220 (106–359) | <.001 |
| Recipient time since transplant (days) | 84 (32–164) | 224 (111–361) | <.001 |
| KDPI (%) | 40 (16–57) | 40 (18–64) | .130 |
| LV ejection fraction (%) | 60 (55–65) | 60 (55–65) | .264 |
Abbreviations: CNS, central nervous system; CPR, cardiopulmonary resuscitation; DCD, donation after cardiac death; KDPI, Kidney Donor Profile Index; LV, left ventricle; NAT, nucleic acid test.
*
Chi‐square test.
**
Other = location not indicated.
***
Kruskal‐Wallis test.